NO154090B - Nye n-heterocyklyl-4-piperidinaminer som er mellomprodukter ved fremstilling av analoge forbindelser. - Google Patents
Nye n-heterocyklyl-4-piperidinaminer som er mellomprodukter ved fremstilling av analoge forbindelser. Download PDFInfo
- Publication number
- NO154090B NO154090B NO842563A NO842563A NO154090B NO 154090 B NO154090 B NO 154090B NO 842563 A NO842563 A NO 842563A NO 842563 A NO842563 A NO 842563A NO 154090 B NO154090 B NO 154090B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- group
- hydrogen
- aryl
- benzimidazol
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 title description 8
- 239000000543 intermediate Substances 0.000 title description 4
- -1 3-cyano-3,3-diphenyl propyl Chemical group 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 2
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005110 aryl thio group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000002844 melting Methods 0.000 description 40
- 230000008018 melting Effects 0.000 description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 150000003585 thioureas Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- PYECMAVHMMXGMT-UHFFFAOYSA-N 4-isothiocyanatopiperidine Chemical compound S=C=NC1CCNCC1 PYECMAVHMMXGMT-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZWOBTWLZWFIELC-UHFFFAOYSA-N 1-(1-chloroethyl)-4-fluorobenzene Chemical compound CC(Cl)C1=CC=C(F)C=C1 ZWOBTWLZWFIELC-UHFFFAOYSA-N 0.000 description 1
- UHPMDEPYHTTWOB-UHFFFAOYSA-N 1-(furan-2-ylmethyl)-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1CNCCC1NC1=NC2=CC=CC=C2N1CC1=CC=CO1 UHPMDEPYHTTWOB-UHFFFAOYSA-N 0.000 description 1
- OMELNWRDUGTZMS-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1CNCCC1NC1=NC2=CC=CC=C2N1CC=1C=COC=1 OMELNWRDUGTZMS-UHFFFAOYSA-N 0.000 description 1
- CQGDDRKARGSSPQ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-5-methoxy-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1CNCCC1NC1=NC2=CC(OC)=CC=C2N1CC1=CC=C(F)C=C1 CQGDDRKARGSSPQ-UHFFFAOYSA-N 0.000 description 1
- WGSZJJLZFHMBIQ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-5-methyl-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1CNCCC1NC1=NC2=CC(C)=CC=C2N1CC1=CC=C(F)C=C1 WGSZJJLZFHMBIQ-UHFFFAOYSA-N 0.000 description 1
- NMEWDSULVJVGQM-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-6-methoxy-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C=1C=C(F)C=CC=1CN1C2=CC(OC)=CC=C2N=C1NC1CCNCC1 NMEWDSULVJVGQM-UHFFFAOYSA-N 0.000 description 1
- SGBPHZODONJHFM-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-methyl-n-piperidin-4-ylbenzimidazol-2-amine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.N=1C2=CC=CC=C2N(CC=2C=CC(F)=CC=2)C=1N(C)C1CCNCC1 SGBPHZODONJHFM-UHFFFAOYSA-N 0.000 description 1
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 1
- JNEFOSFNMBCIBT-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 JNEFOSFNMBCIBT-UHFFFAOYSA-N 0.000 description 1
- CBWJHIXSVFDERH-UHFFFAOYSA-N 1-isothiocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1N=C=S CBWJHIXSVFDERH-UHFFFAOYSA-N 0.000 description 1
- XFEKIQFBJSDMQB-UHFFFAOYSA-N 2,2,2-trichloroethylbenzene Chemical compound ClC(Cl)(Cl)CC1=CC=CC=C1 XFEKIQFBJSDMQB-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BUXFYHBOUXYJGQ-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-n-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1=CC(F)=CC=C1CN1C2=NC=CC=C2N=C1NC1CCNCC1 BUXFYHBOUXYJGQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- MCPCXGMTSNUIAD-UHFFFAOYSA-N NC1=NC=CC=C1.Br.Br.Br Chemical compound NC1=NC=CC=C1.Br.Br.Br MCPCXGMTSNUIAD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- QHEBWROVPAWODK-UHFFFAOYSA-N benzyl 4-[[[2-[(4-fluorophenyl)methylamino]pyridin-3-yl]amino]-methanethioylamino]piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CNC1=NC=CC=C1NN(C=S)C1CCN(C(=O)OCC=2C=CC=CC=2)CC1 QHEBWROVPAWODK-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GPUYTVOFCHCLIF-UHFFFAOYSA-N ethyl 4-(1h-benzimidazol-2-ylmethylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCC1=NC2=CC=CC=C2N1 GPUYTVOFCHCLIF-UHFFFAOYSA-N 0.000 description 1
- DDIAAZFNMXCNOX-UHFFFAOYSA-N ethyl 4-[(1-benzyl-5-chlorobenzimidazol-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(Cl)=CC=C2N1CC1=CC=CC=C1 DDIAAZFNMXCNOX-UHFFFAOYSA-N 0.000 description 1
- ONNYNYRQIMHRON-UHFFFAOYSA-N ethyl 4-[(1-phenylbenzimidazol-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1C1=CC=CC=C1 ONNYNYRQIMHRON-UHFFFAOYSA-N 0.000 description 1
- MTAZKVTUGXRDSU-UHFFFAOYSA-N ethyl 4-[(2-aminophenyl)carbamothioylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=S)NC1=CC=CC=C1N MTAZKVTUGXRDSU-UHFFFAOYSA-N 0.000 description 1
- GOPHJAFXOPBEHA-UHFFFAOYSA-N ethyl 4-[(3-benzylimidazo[4,5-b]pyridin-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CN=C2N1CC1=CC=CC=C1 GOPHJAFXOPBEHA-UHFFFAOYSA-N 0.000 description 1
- BLQLBGJODBPYFR-UHFFFAOYSA-N ethyl 4-[(6-chloro-1h-benzimidazol-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(Cl)=CC=C2N1 BLQLBGJODBPYFR-UHFFFAOYSA-N 0.000 description 1
- GDEBHSGKCAZXEQ-UHFFFAOYSA-N ethyl 4-[(6-fluoro-1h-benzimidazol-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(F)=CC=C2N1 GDEBHSGKCAZXEQ-UHFFFAOYSA-N 0.000 description 1
- SHESZUAEWMVGSW-UHFFFAOYSA-N ethyl 4-[(6-methyl-1h-benzimidazol-2-yl)amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(C)=CC=C2N1 SHESZUAEWMVGSW-UHFFFAOYSA-N 0.000 description 1
- WUFBIABUUNHTCX-UHFFFAOYSA-N ethyl 4-[4-(1h-benzimidazol-2-yl)butylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCCCCC1=NC2=CC=CC=C2N1 WUFBIABUUNHTCX-UHFFFAOYSA-N 0.000 description 1
- KMMCSHWHRVGLMQ-UHFFFAOYSA-N ethyl 4-[[1-(4-fluorophenyl)benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1C1=CC=C(F)C=C1 KMMCSHWHRVGLMQ-UHFFFAOYSA-N 0.000 description 1
- DSAVISNDOMINMS-UHFFFAOYSA-N ethyl 4-[[1-(furan-3-ylmethyl)benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1CC1=COC=C1 DSAVISNDOMINMS-UHFFFAOYSA-N 0.000 description 1
- ZKFIBPYAVAORIM-UHFFFAOYSA-N ethyl 4-[[1-(pyridin-3-ylmethyl)benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1CC1=CC=CN=C1 ZKFIBPYAVAORIM-UHFFFAOYSA-N 0.000 description 1
- WZIUCUHDRKHTJM-UHFFFAOYSA-N ethyl 4-[[1-(thiophen-2-ylmethyl)benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CC=C2N1CC1=CC=CS1 WZIUCUHDRKHTJM-UHFFFAOYSA-N 0.000 description 1
- ASTSGPPOUQVJOC-UHFFFAOYSA-N ethyl 4-[[1-[(4-fluorophenyl)methyl]-5-methylbenzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(C)=CC=C2N1CC1=CC=C(F)C=C1 ASTSGPPOUQVJOC-UHFFFAOYSA-N 0.000 description 1
- UWJCLPBNMYQVON-UHFFFAOYSA-N ethyl 4-[[1-[(4-fluorophenyl)methyl]-6-methoxybenzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=C(OC)C=C2N1CC1=CC=C(F)C=C1 UWJCLPBNMYQVON-UHFFFAOYSA-N 0.000 description 1
- NEEZBYBEZAVOAT-UHFFFAOYSA-N ethyl 4-[[1-benzyl-5-(trifluoromethyl)benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(C(F)(F)F)=CC=C2N1CC1=CC=CC=C1 NEEZBYBEZAVOAT-UHFFFAOYSA-N 0.000 description 1
- GXJMPQZIWQBEGG-UHFFFAOYSA-N ethyl 4-[[3-(pyridin-2-ylmethyl)imidazo[4,5-b]pyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CN=C2N1CC1=CC=CC=N1 GXJMPQZIWQBEGG-UHFFFAOYSA-N 0.000 description 1
- DLZZKAKXHKQMGG-UHFFFAOYSA-N ethyl 4-[[3-[(4-fluorophenyl)methyl]imidazo[4,5-b]pyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC=CN=C2N1CC1=CC=C(F)C=C1 DLZZKAKXHKQMGG-UHFFFAOYSA-N 0.000 description 1
- FAZUYZBTSGCVSX-UHFFFAOYSA-N ethyl 4-[[5-chloro-1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC2=CC(Cl)=CC=C2N1CC1=CC=C(F)C=C1 FAZUYZBTSGCVSX-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- YCDPBTSAQFQAOG-UHFFFAOYSA-N methyl 4-(1h-benzimidazol-2-ylamino)-3-methylpiperidine-1-carboxylate Chemical compound CC1CN(C(=O)OC)CCC1NC1=NC2=CC=CC=C2N1 YCDPBTSAQFQAOG-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YARZJBYWEQWRMV-UHFFFAOYSA-N n-benzyl-n-piperidin-4-yl-1h-benzimidazol-2-amine Chemical compound C=1C=CC=CC=1CN(C=1NC2=CC=CC=C2N=1)C1CCNCC1 YARZJBYWEQWRMV-UHFFFAOYSA-N 0.000 description 1
- QRGLDPVAEILBCX-UHFFFAOYSA-N n-piperidin-4-yl-1-(pyridin-2-ylmethyl)benzimidazol-2-amine;trihydrobromide Chemical compound Br.Br.Br.C1CNCCC1NC1=NC2=CC=CC=C2N1CC1=CC=CC=N1 QRGLDPVAEILBCX-UHFFFAOYSA-N 0.000 description 1
- XPPWQBBOOXZHMB-UHFFFAOYSA-N n-piperidin-4-yl-1-(pyridin-3-ylmethyl)benzimidazol-2-amine;trihydrobromide Chemical compound Br.Br.Br.C1CNCCC1NC1=NC2=CC=CC=C2N1CC1=CC=CN=C1 XPPWQBBOOXZHMB-UHFFFAOYSA-N 0.000 description 1
- TUSONZDXFJHASK-UHFFFAOYSA-N n-piperidin-4-yl-1-(thiophen-2-ylmethyl)benzimidazol-2-amine Chemical compound C1CNCCC1NC1=NC2=CC=CC=C2N1CC1=CC=CS1 TUSONZDXFJHASK-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Description
Foreliggende oppfinnelse angår nye mellomprodukter i form av N-heterocyklyl-4-piperidinaminer til bruk ved fremstilling av en ny serie andre N-heterocyklyl-4-piperidinaminer som strukturelt representeres ved formelen:
og farmasøytisk akseptable syreaddisjonssalter derav, der R er hydrogen eller metyl; R"*" er hydrogen eller laverealkyl med 1 til 6 karbonatomer; R 2 er hydrogen, alkyl med 1 til 10 karbonatomer, cykloalkyl med 3 til 6 karbonatomer, aryl, mono- eller diaryl C^_g lavere alkyl, hvori arylgruppen er fenyl, som valgfritt kan være substituert med 1 til 2 substituenter som er halogenatomer eller metyl- eller nitrogrupper; R^ er hydrogen, halogen, metyl eller trifluormetyl; L er en laverealkylgruppe som inneholder 1 til 6 karbonatomer og eventuelt er substituert med en cyano- eller hydroksygruppe eller en C^_4 lavere alkoksygruppe, C^_^ lavere alkylkarbonyloksygruppe eller en aryl-, aryloksy-, aryltio- eller aminogruppe; difenyl C^_g laverealkyl; di-(halogenfenyl)C^_glaverealkyl; 3-cyano-3,3-difenyl propyl; 2-propenyl; 3-aryl-2-propenyl; 3-aryloksy-2-hydroksy propyl; eller en gruppe med formelen:
m er et helt tall fra 1 til 4; og
Q er CH eller N; og
Z er 4-aryl-4,5-dihydro-5-okso-lH-tetrazol-l-yl, 4-(C^_^
laverealkyl)-4,5-dihydro-5-okso-lH-tetrazol-l-yl-2,3-dihydro-1,4-benzodioksy-2-yl; 2,3-dihydro-l,4-benzodiokin-6-yl; 2,3-dihydro-2-okso-lH-benzimidazol-l-yl; 2,3-di-hydro-3-okso-4H-benzoksazin-4-yl; (10,ll-dihydro-5H-dir benzo[a,J] cyklohepten-5-yliden)-metyl; 4-morfoinyl;
arylkarbonyl; arylaminokarbonyl, C^_4-lavere alkylamino-karbonylamino; arylkarbonylamino; arylaminokarbonylamino;
^-lavere alkylkarbonylamino; aminokarbonylaminq eller arylamino, hvorved når L er en med en arylgruppe substituert lavere alkylgruppe med 1-6 karbonatomer betegner arylgruppen fenyl, substituert fenyl, naftalenyl, tienyl eller pyridinyl, hvorved nevnte substituerte fenyl inneholder 1-3 substituenter som uavhengig av hverandre er halogenatomer eller metyl-, C^_4 lavere alkyloksy-, trifluormetyl-, hydroksy-, nitro- eller aminogrupper, og hvorved en av substituentene dessuten kan være metyltio, C^_^ laverealkyloksy, karbonylmetoksy, fenylacetyloksy, benzyloksy, metoksybenzoyloksy, fenylmetoksy, C^_^ lavere alkyloksykarbonyloksy, fenylmetoksykarbonyloksy, metyl-sulfonyl eller cyanometoksy, og hvorved aryl i alle andre definisjoner av L betyr en fenylgruppe, som eventuelt er mono- eller di-substituert, hvorved hver substituent uavhengig av hverandre er et halogenatom eller en metyl-eller metoksygruppe.
Som brukt i de ovenfor angitte -definisjoner er uttrykket "lavere alkyl" ment å inkludere rette og forgrenete hydrokarbonrester med fra 1 til 6 karbonatomer slik som f.eks. metyl, etyl, 1-metyletyl, 1,1-dimetyletyl, propyl, 2-metyl-propyl, butyl, pentyl, heksyl o.l.; uttrykket "alkyl" som brukt i -,:.definisjonen av R 2inkluderer rette og forgrenete hydrokarbonrester med fra 1 til 10 karbonatomer, slik som f.eks. de ovenfor angitte lavere alkyler og høyere homologer slik som heptyl, oktyl, nonyl og decyl; uttrykket "lavere alkenyl" angir rette alkenylrester med fra 3 til 6 karbonatomer hvori umettetheten fortrinnsvis befinner seg i 6-stilling, men også kan befinne seg. i y, 8 eller e-stilling slik som f.eks. 2-propenyl, 2-butenyl, 3-pentenyl, 2-heksenyl o.l.; uttrykket "cykloalkyl" angir cykliske hydrokarbonrester med fra 3 til 6 karbonatomer slik som cyklopropyl, cyklobutyl, cyklopentyl og cykloheksyl, og uttrykket "halogen" angir fluor, klor, brom og jod.
Forbindelsene med formel (I) kan således generelt avledes fra en utgangsforbindelse ifølge oppfinnelsen med formelen
12 3
der R, R , R , R og Q er som angitt ovenfor og L er valgt blant hydrogen, laverealkyloksykarbonyl og fenylmetoksykarbonyl.
Generelt kan innføringen av L i mellomproduktet (Ila) hvor
L^" er hydrogen, hensiktsmessig skje ved omsetningen av for^ . bindelse (Ila) hvor L^" er hydrogen, med en egnet reaktiv ester med formelen LY, (III), der L er som angitt ovenfor og Y er reaktiv esterrest slik som f.eks. halogen, fortrinnsvis klor eller brom, eller en sulfonyloksyrest slik som f.eks. metylsulfonyloksy eller 4-metylfenylsulfonyloksy o.l.
Kondensasjonen mellom (Ila) hvor L"'" er hydrogen og (III) gjennomføres hensiktsmessig i et inert organisk oppløsnings-middel slik som f.eks. et aromatisk hydrokarbon, f.eks. benzen, metylbenzen, dimetylbenzen o.l., en lavere alkanol, f.eks. metanol, etanol, 1-butanol o.l.; et keton, f.eks. 4-metyl-2-pentanon o.l.; en eter, f.eks. 1,4-dioksan, 1,1'-oksybisetan o.l.; N,N-dimetylformamid (DMF); nitrobenzen o.l.
Tilsetningen av en egnet base slik som f.eks. et alkalime-tallkarbonat eller -hydrogenkarbonat, eller en organisk base slik som f.eks. N,N-dietyletanamin eller N-(l-metyletyl)-2-propanamin kan benyttes for å fange opp syren som settes fri under reaksjonen. Under visse betingelser er tilsetning av et jodsalt, fortrinnsvis et alkalimetal1jodid, å anbefale. Noe forhøyede temperaturer kan benyttes for å øke reaksjonshastigheten.
Mellomproduktene ifølge oppfinnelsen med formel (Ila) hvor L er lavere alkoksykarbonyl og fenylmetoksykarbonyl, beteg-nes som P, kan generelt fremstilles ved å gå ut fra et tio-urinstoffderivat med formel (X) hvori R, R 1, R 2 og R 3 er som angitt ovenfor og P er som angitt en lavere alkyloksy-karbonyl eller fenylmetoksykarbonyl, ved å underkaste (X)
en cyklodesulfureringsreaksjon for å oppnå et mellomprodukt med formel (X) og deretter, når dette ønskes, eliminere P på vanlig måte.
Cyklodesulfureringen av (X) for å oppnå (XI) kan utføres
på kjent måte. For å fjerne P kan det, når P er en lavere alkyloksykarbonylgruppe, benyttes alkalisk eller fortrinnsvis sur hydrolyse, f.eks. ved bruk av hydrobromsyre i is-eddik, og når P er fenylmetoksykarbonylgruppe, kan den fjer-nes ved alkalisk eller sur hydrolyse eller ved katalytisk hydrogenering ved bruk av en egnet katalysator slik som palladium-på-trekull.
Mellomproduktene med formel (XI) der R 2 er forskjellig fra hydrogen kan også avledes fra den tilsvarende forbindelse (XI) der R 2 er hydrogen ved innføring av den ønskede R 2-substituent i henhold til i og for seg kjente metoder som beskrevet ovenfor i forbindelse med fremstilling av forbind-elsen (I-a) ut fra (I-b).
Tiourinstoffderivatene med formel (X) der R angir hydrogen,
(X-a), kan fremstilles ved omsetning av et egnet 4-isotio-cyanatopiperidin med formel (XII) med et egnet benzendiamin eller pyridindiamin med formelen (XIII), f.eks. ved enkelt omrøring av reaktantene sammen i et egnet organisk oppløs-ningsmiddel, slik som f.eks. en lavere alkanol, f.eks. metanol, etanol, 2-propanol o.l.
Tiourinstoffderivatene med formel (X) der R er som angitt ovenfor og R 2 er hydrogen, (X-b), kan fremstilles ved omsetning av et egnet 4-piperidinamin med formeln (XIV) med en egnet l-isotiocyanato-2-nitrobenzen med formelen (XV), fulgt av reduksjon av ritrogruppen av den således oppnådde forbindelse (XVI) ifølge velkjente nitro-tiamin-reduksjonspro-sedyrer, slik som f.eks. ved reaksjonen av (XVI) med nascer-ende hydrogen eller ved katalytisk hydrogenering ved bruk av en egnet katalysator slik som f.eks. palladium-på-trekull o.l., eller i nærvær av en mer enn en slik katalysator. Forløpsstoffene med formel (XIV) kan fremstilles i henhold til i og for seg kjente metoder, f.eks. ved reduktiv aminering av det tilsvarende 4-piperidinon. 4-isotiocyanatopiperidinene med formel (XII) kan igjen fremstilles ved å gå ut fra den tilsvarende forbindelse (XIV) der R<1> er hydrogen gjennom stan-dardmetoder for fremstilling av isotiocyanater fra primære aminer, f.eks. ved reaksjon av aminet med karbondisulfid i alkalisk medium og etterfølgende tilsetning til reaksjonsblandingen av et egnet lavere alkylkarbonkloridat eller med fenylmetylkarbonkloridat.
De følgende eksempler skal illustrere oppfinnelsen .
Hvis ikke.annet er angitt, er alle delangivelsene på vektbasis.
Eksempel 1
En blanding av 23 deler (fenylmetyl)-4-[{2-[(4-fluorfenyl-metyl)amino]-3-pyridinylamino}tioksometylamino]-1-piperidin-karboksylat, 17 deler kvikksølvoksyd, 0,1 del svovel og 450 deler tetrahydrofuran omrøres og kokes under tilbakeløp i 1 time. Reaksjonsblandingen filtreres over "Hyflo" og filtratet fordampes. Resten krystalliseres fra en blanding av 4-metyl-2-pentanon og 2,2<1->oksybispropan. Produktet filtreres av og tørkes og man oppnår 20 deler eller 93% (fenyl-metyl )-4-[3-4-fluorfenylmetyl)-3H-imidazo[4,5-b]-pyridin-2-ylamino]-1-piperidinkarboksylat med smeltepunkt 130°C.
Eksempel 2
Ved å følge prosedyren i eksempel 1. og ved å bruke ekvivalente mengder av de egnete utgangsstoffer fremstilles: ety1-4-[(lH-benzimidazol-2-y1)metylamino]-1-piperidinkarbok-sylat; etyl-4-[(lH-benzimidazol-2-yl)butylamino]-1-piperidinkarbok-sylat; smeltepunkt 225,9°C; etyl-4-[l-(fenylmetyl)-5-(trifluormetyl)-lH-benzimidazol-2-ylamino]-1-piperidinkarboksylat med smeltepunkt 200°C; etyl-4-(5-fluor-lH-benzimidazol-2-ylamino)-1-piperidin-karboksylat med smeltepunkt 227,5°C; etyl-4-[5-klor-1-(fenylmetyl)-lH-benzimidazol-2-ylamino]-1-piperidinkarboksylat med smeltepunkt 211,9°C; etyl-4-[3-(fenylmetyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-1-piperidinkarboksylat med smeltepunkt 148,6°C; etyl-4-[5-klor-1-(4-fluorfenylmetyl)-lH-benzimidazol-2-yl-amino]-1-piperidinkarboksylat med smeltepunkt 215,8°C; metyl-4-(lH-benzimidazol-2-ylamino)-3-metyl-1-piperidinkarbok-sylat med smeltepunkt 155°C; etyl-4-[3-(4-fluorfenylmetyl)-3H-imidazo[4,5-b]pyridin-2-ylamino] -1-piperidinkarboksylat med smeltepunkt 134,4°C; etyl-4-[(3H-imidazo[4,5-b]pyridin-2-yl)amino]-l-pyridin-karboksylat med smeltepunkt 216,1°C;
etyl-4-(l-fenyl-lH-benzimidazol-2-ylamino)-1-piperidinkarbok-sylat med smeltepunkt 137°C; og
etyl-4-[1-(4-fluorfeny1)-lH-benzimidazol-2-ylamino]-1-pipe-ridinkarboksylat med smeltepunkt 153°C.
Eksempel 3
En blanding av 28 deler etyl-4-{[(2-aminofenyl)-aminotiokso-metyl]amino}-1-piperidinkarboksylat, 112 deler jodmetan og 240 deler etanol omrøres og kokes under tilbakeløp i 8 timer. Reaksjonsblandingen fordampes og resten tas opp i vann. Det hele gjøres alkalisk med ammoniumhydroksyd og produktet ekstraheres med diklormetan. Ekstrakten tørkes, filtreres og fordampes. Resten krystalliseres fra en blanding av 2-propanol og 2,2'-oksybispropan. Produktet filtreres av og tørkes og man oppnår 7 deler eller 28% etyl-4-(lH-benzimidazol-2-
yl-amino)-1-piperidinkarboksylat.
Ved å følge den samme prosedyre og ved å bruke ekvivalente mengder av de egnete utgangsstoffer fremstilles: etyl-4-(5-klor-lH-benzimidazol-2-ylamino)-1-piperidinkarboksylat med smeltepunkt 234 , 1°C; og etyl-4-(5-metyl-lH-benzimidazol-2-ylamino)-1-piperidinkarboksy-lat.
Ved å følge den prosedyre som er beskrevet i eksempel 1, fremstilles også:
Eksempel 4
En blanding av 1,6 deler 1-(1-kloretyl)-4-fluorbenzen, 3,2 deler N-[l-(2-fenyletyl)-4-piperidiny1 | -IH-benzimidazol-2-amin, 1 del- natriumkarbonat, 0,1 deler kaliumjodid og 120 deler 4-metyl-2-pentanon omrøres og kokes under tilbake-løp over natt med vann separator. Reaksjonsblandingen av-kjøles, helles på vann og sjiktene separeres. Den organiske fase tørkes, filtreres og fordampes. Resten renses ved kolonnekromatografi over silikagel ved bruk av en 98:2 volum-blanding av triklormetan og metanol som elueringsmiddel.
De rene fraksjoner samles og elueringsmidlet fordampes. Resten krystalliseres fra 2,2'-oksybispropan. Produktet filtreres og tørkes og man oppnår 1,8 deler eller 40,7% 1-[1-(4-fluorfeny1)etyl]-N-[1-(2-fenyletyl)-4-piperi-diny1]-lH-benzoimidazol-2-amin med smp. 161,7°C.
Eksempel 5.
Ved å følge prosedyren i eksempel 4 og ved å bruke ekviva-lente mengder av de egnede utgangsstoffer oppnås de følgende forbindelser i form av frie baser eller i form av syreaddisjonssalter med omsetning av den frie base med en egnet syre.
På tilsvarende måte fremstilles også: 5(6)-fluor-1-(4-fluorfenylmetyl)-N-(4-piperidinyl)-lH-benz-imidazol-2-amin dihydrobromid; smeltepunkt 285,6°C; 3-(4-fluorfenylmetyl)-N-(4-piperidinyl)-3H-imidazo[4,5-b ] pyridin-2-amin dihydroklorid monohydrat; smeltepunkt 269,7°C; etyl 4-[1-(2-fenyletyl)-lH-benzimidazol-2-ylamino ]-l-piperi-din-karboksyl monohydrat; smeltepunkt 71,2°C; l-(2-fenyletyl)-N-(4-piperidinyl)-lH-benzimidazol-2-amin; smeltepunkt 181,8°C;
etyl 4-[l- 2-(4-fluorfenyl)etyl]-lH-benzimidazol-2-ylamino - 1-piperidinkarboksyl; smeltepunkt 110,2°C;
etyl 4-[[1-[(3-fluorfenyl)metyl]-lH-benzimidazol-2-ylamino]-1-piperidinkarboksylat; smeltepunkt 184,6°C; 1- [(3-fluorfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin; smeltepunkt 218,4°C;
etyl 4-[(5-metoksy-lH-benzimidazol-2-yl)amino]1-piperidin-karboksylat ;
etyl 4-[[l-[(4-fluorfenyl)metyl]-5(6)-metoksy-lH-benzimidazol-2- yl]amino]-1-piperidinkarboksylat; smeltepunkt 169,8°C;
etyl 4-[[1-(2-pyridinylmetyl)-lH-benzimidazol-2-yljamino]-l-piperidinkarboksylat; smeltepunkt 161,5°C;
N-(4-piperidinyl)-l-(2-pyridinylmetyl)-lH-benzimidazol-2-amin trihydrobromid; smeltepunkt 295,9°C;
etyl 4-[[1-(3-pyridinylmetyl)-lH-benzimidazol-2-yl] amino]-l-piperidinkarboksylat; smeltepunkt 191,4°C,
N-(4-piperidinyl)-1-(3-pyridinylmetyl)-lH-benzimidazol-2-amin trihydrobromid; smeltepunkt + 260°C;
etyl 4-[[1-(2-furanylmetyl)-lH-benzimidazol-2-yl1amino]-1-piperidinkarboksylat; smeltepunkt 135,8°C;
1-(2-furanylmetyl)-N-(4-piperidinyl)-lH-benzimidazol-2-amin; smeltepunkt +260°C;
1-[(4-flurofenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin; smeltepunkt 215,5°C;
etyl 4-[[3-(2-pyridinylmetyl)-3H-imidazo[4,5-b]pyridin-2-yl]-amino]-1-piperidinkarboksylat; smeltepunkt 141,3°C; N-(4-piperidnyl)-3-(2-pyridinylmetyl)-3H-imidazo 4,5-b pyridin-2-amin trihydrobromid; smeltepunkt 265,5°C; etyl-[(5,6-difluor-lH-benzimidazol-2-yl)amino ]-1-piperidin-
karboksylat; smeltepunkt 234,9°C;
etyl 4-[[[5,6-difluor-1-(4-flurofenyl)metyl]-lH-benzimidazol-2- yl]amino]-1-piperidinkarboksy1; smeltepunkt 182,3°C;
etyl 4-[[3-(2-furanylmetyl)-3H-imidazo[4,5-b]pyridin-2-yl]-amino]-1-piperidinkarboksyl; smeltepunkt 149,2°C; 3- (2-furanylmetyl)-N-(4-piperidinyl)-3H-imidazo 4,5-b pyridin-2-amin; smeltepunkt 159,0°C;
5,6-difluor-1-[(4-fluorfenyl)metyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amin dihydrobromid; smeltepunkt 210,6°C;
etyl 4-[[l- (4-fluorfenyl metyl)-5-metoksy-lH-benzimidazol-2-ylJamino]-1-piperidinkarboksylat;
etyl 4-[[1-(2-tienylmetyl)-lH-benzimidazol-2-yl]amino]-1-pipe-ridinkarboksylat ; smeltepunkt 142,7°C;
N-(4-piperidinyl)-l-(2-tienylmetyl)-lH-benzimidazol-2-amin; etyl 4-[[l-[(4-fluorfenyl)metyl]-6-metoksy-lH-benzimidazol-2-yl]amino]-l-piperidinkårboksylat;
etyl 4-[[1-(3-furanylmetyl)-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat, smeltepunkt 150,7°C;
1- (3-furanylmetyl)-N-(4-piperidinyl)-lH-benzimidazol-2-amin,• etyl 4-[[3-(2-tienylmetyl)-3H-imidazol[4,5-b]pyridin-2-yl]-amino]-1-piperidinkarboksylat som en rest;
N-(4-piperidinyl)-3-(2-tienylmetyl)-3H-imidazo 4,5-b pyridin-2- amin, smeltepunkt 189,6-193,5°C;
etyl 4-[[1-[(4-metoksyfeny1)metyl]-lH-benzimidazol-2-yl]-amino]
-1-piperidinkarboksylat; smeltepunkt 157,1°C; 1- [(4-metoksyfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2- amin; smeltepunkt 178,1°C; 1-[(4-fluorfenyl)metyl]-5-metoksy-N-(4-piperidinyl)-lH-benzi-midazol-2-amin;
etyl 4-[[l-[(4-fluorfenyl)metyl]-lH-benzimidazol-2-yljmetyl-amino]-1-piperidinkarboksylat som en rest; 1-[(4-fluorfenyl)metyl]-N-metyl-N-(4-piperidinyl)-lH-benzimi-dazol-2-amin dihydroklorid monohydrat, smeltepunkt 222,2°C; 1 -[(4-fluorfenyl)metyl]-6-metoksy-N-(4-piperidinyl)-lH-benz-imidazol-2-amin;
etyl 4-t (lH-benzimidazol-2-yl)(fenylmetyl)amino]-1-piperidin-' karboksylat;
N-(fenylmetyl)-N-(4-piperidinyl)-lH-benzimidazol-2-amin;
etyl 4-[[l-[(3-klorfenyl)metyl]-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat;
l-[ (3-klorfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin dihydrobromid; smeltepunkt 262,2°C;
etyl 4-[[l-[(3,4-dimetylfenyl)metyl]-lH-benzimidazol-2-yl]-amino]-1-piperidinkarboksylat; 1- [(3,4-dimetylfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2- amin dihydrobromid;
etyl 4-[[l-[(2-metylfenyl)metyl]-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat;
etyl 4-[[l-[(2-metylfenyl)metyl]-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat; l-[(2-metylfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin dihydrobromid;
etyl 4-[[l-[(3-metylfenyl)metyl]-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat; 1-[(3-metylfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin dihydrobromid;
etyl 4-[[1-[ (2-brom-4-flurofenyl)metyl]-lH-benzimidazol-2-yl] -amino]-1-piperidinkarboksylat; l-[(2-brom-4-flurofenyl)metyl]-N-(4-piperidinyl)-lH-benzimida-zol-2-amin dihydrobromid; som en rest;
etyl 4-[[1-[(2-iodofenyl)metyl]-lH-benzimidazol-2-yl]amino]-1-piperidinkarboksylat;
1-[(2-iodofenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2-amin dihydrobromid dihydrat, smeltepunkt 265,2°C;
etyl 4-[[1-[(4-fluorfenyl)metyl]-5-metyl-lH-benzimidazol-2-yl] amino]-1-piperidinkarboksylat; smeltepunkt 202°C; 1-[(4-fluorfenyl)metyl]-5-metyl-N-(4-piperidinyl)-lH-benzimi-dazol-2-amin; som en rest;
etyl 4-[[1-[(2,4-diklorfenyl)metyl]-lH-benzimidazol-2-yl]-amino]-1-piperidinkarboksylat;
1- [(2,4-diklorfenyl)metyl]-N-(4-piperidinyl)-lH-benzimidazol-2- amin dihydrobromid; smeltepunkt 225,6°C;
etyl 4-[[1-[(2,6-difluorfeny1)metyl]-lH-benzimidazol-2-yl]-amino]-1-piperidinkarboksylat; smeltepunkt 140°C; og 1-[(2,6-difluorfenyl)metyl]-N-(4-piperidinyl)-lH-benzimida-zol-2-amin dihydrobromid, smeltepunkt 295,5°C.
Claims (1)
1. Mellomprodukt for fremstilling av N-heterocykly1-4-piperidinaminer med formelen:
og farmasøytisk akseptable syreaddisjonssalter derav der R er hydrogen eller metyl;
R 1 er hydrogen eller laverealkyl med 1 til 6 karbonatomer; R 2 er hydrogen, alkyl med 1 til 10 karbonatomer, cykloalkyl
med 3 til 6 karbonatomer, aryl, mono- eller diaryl C-|__g lavere alkyl, hvori arylgruppen er fenyl, som valgfritt kan være substituert med 1 til 2 substituenter som er halogenatomer eller metyl- eller nitrogrupper; R"^ er hydrogen, halogen, metyl eller trif luormetyl;
L er en lavere alkylgruppe som inneholder 1 til 6 karbon
atomer og eventuelt er substituert med en cyano- eller hydroksygruppe eller en C-^_^ lavere alkoksygruppe, C^_^ lavere alkylkarbonyloksygruppe eller en aryl-, aryloksy-, aryltio- eller aminogruppe; difenyl c^_g laverealkyl; di-(halogenfenyl)Cglaverealkyl; 3-cyano-3,3-difenyl propyl; 2-propenyl; 3-aryl-2-propenyl; 3-aryloksy-2-hydroksy propyl; eller en gruppe med formelen:
m er et helt tall fra 1 til 4; og
Q er CH eller N; og
Z er 4-aryl-4,5-dihydro-5-okso-lH-tetrazol-l-yl, 4_(c^_4
laverealkyl)-4,5-dihydro-5-okso-lH-tetrazol-l-yl-2,3-dihydro-l,4-benzodioksy-2-yl; 2,3-dihydro-l,4-benzodiokin-6-yl; 2,3-dihydro-2-okso-lH-benzimidazol-l-yl; 2,3-di-hydro-3-okso-4H-benzokinazin-4-yl; (10,ll-dihydro-5H-dibenzo[a,d| cyklohepten-5-yliden)-metyl; 4-morfoinyl; arylkarbony1; arylaminokarbony1, C^_^-lavere alkylamino-karbonylamino; arylkarbonylamino; arylaminokarbonylamino; C^_^ -lavere alkylkarbonylamino; aminokarbonylamino eller arylamino, hvorved når L er en med en arylgruppe substituert lavere alkylgruppe med 1-6 karbonatomer betegner arylgruppen fenyl, substituert fenyl, naftalenyl, tienyl eller pyridinyl, hvorved nevnte substituerte fenyl inneholder 1-3 substituenter som uavhengig av hverandre er halogenatomer eller metyl-, C^_4 lavere alkyloksy-, trifluormetyl-, hydroksy-, nitro- eller aminogrupper, og hvorved en av substituentene dessuten kan være metyltio, C-j__4 laverealkyloksy, karbonylmetoksy, fenylacetyloksy, benzyloksy, metoksybenzoyloksy, fenylmetoksy, C^_^ lavere alkyloksykarbonyloksy, fenylmetoksykarbonyloksy, metyl-sulfonyl eller cyanometoksy, og hvorved aryl i alle andre definisjoner av L betyr en fenylgruppe, som eventuelt er mono- eller di-substituert, hvorved hver substituent uavhengig av'hverandre er et halogenatom eller en metyl-eller metoksygruppe, karakterisert ved at det har formelen:
der L"^ er valgt blant hydrogen, laverealkoksykarbonyl og fenyl
metoksykarbonyl;
R er valgt blant hydrogen eller metyl; R"*" er valgt blant hydrogen eller lavere alkyl med 1-6 karbon
atomer ;
R 2 er valgt blant hydrogen, alkyl med fra 1-10 karbonatomer,
cykloalkyl med 3-6 karbonatomer, aryl, mono- eller diaryl C^_g lavere alkyl hvori aryl-gruppen er fenyl som valgfritt kan være substituert med 1-2 substituenter
som er halogenatomer, eller metyl- eller nitro-grupper;
R 3 uavhengig er valgt blant hydrogen, halogen, metyl eller
trifluormetyl; og
Q er valgt blant C og N.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89253478A | 1978-04-03 | 1978-04-03 | |
US06/002,276 US4219559A (en) | 1979-01-10 | 1979-01-10 | N-Heterocyclyl-4-piperidinamines |
Publications (3)
Publication Number | Publication Date |
---|---|
NO842563L NO842563L (no) | 1979-10-04 |
NO154090B true NO154090B (no) | 1986-04-07 |
NO154090C NO154090C (no) | 1986-07-16 |
Family
ID=26670178
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO791097A NO154058C (no) | 1978-04-03 | 1979-04-02 | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-heterocyklyl-4-piperidinaminer. |
NO842563A NO154090C (no) | 1978-04-03 | 1984-06-25 | Nye n-heterocyklyl-4-piperidinaminer som er mellomprodukter ved fremstilling av analoge forbindelser. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO791097A NO154058C (no) | 1978-04-03 | 1979-04-02 | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-heterocyklyl-4-piperidinaminer. |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0005318B1 (no) |
JP (2) | JPS54151982A (no) |
AT (1) | AT373887B (no) |
AU (1) | AU523352B2 (no) |
BG (1) | BG38164A3 (no) |
CA (1) | CA1140119A (no) |
CS (1) | CS256358B2 (no) |
CY (1) | CY1250A (no) |
DE (1) | DE2961740D1 (no) |
DK (1) | DK169325B1 (no) |
EG (1) | EG13913A (no) |
ES (1) | ES479206A1 (no) |
FI (1) | FI64801C (no) |
GR (1) | GR64907B (no) |
HK (1) | HK3184A (no) |
HU (1) | HU182965B (no) |
IE (1) | IE47818B1 (no) |
IL (1) | IL56992A (no) |
MY (1) | MY8500046A (no) |
NO (2) | NO154058C (no) |
NZ (1) | NZ189978A (no) |
PH (1) | PH15877A (no) |
PL (1) | PL123380B1 (no) |
PT (1) | PT69429A (no) |
RO (1) | RO79320A (no) |
SG (1) | SG29883G (no) |
SU (1) | SU1056902A3 (no) |
YU (2) | YU42484B (no) |
ZA (1) | ZA791557B (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA19091A1 (fr) * | 1980-03-10 | 1981-10-01 | Janssen Pharmaceutica Nv | Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine . |
IN156065B (no) * | 1982-07-12 | 1985-05-04 | Janssen Pharmaceutica Nv | |
US4556660A (en) * | 1982-07-12 | 1985-12-03 | Janssen Pharmaceutica N.V. | N-(Bicyclic heterocyclyl)-4-piperidinamines |
US4634704A (en) * | 1983-10-06 | 1987-01-06 | Janssen Pharmaceutica, N.V. | Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines |
EP0144101B1 (en) * | 1983-11-30 | 1991-02-06 | Janssen Pharmaceutica N.V. | Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines |
JPS60174778A (ja) * | 1984-01-09 | 1985-09-09 | ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ | N−ヘテロシクリル−4−ピペリジンアミン |
KR930005004B1 (ko) * | 1985-04-15 | 1993-06-11 | 쟈안센 파아마슈우티카 엔. 부이. | 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법 |
GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
DE3781173T2 (de) * | 1986-02-03 | 1992-12-17 | Janssen Pharmaceutica Nv | N-heterozyklische-4-piperidinamine enthaltende anti-histaminische zusammensetzungen. |
NZ223654A (en) * | 1987-03-09 | 1990-03-27 | Janssen Pharmaceutica Nv | 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions |
FR2618435B1 (fr) * | 1987-07-23 | 1989-10-27 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
US5210091A (en) * | 1991-06-24 | 1993-05-11 | Neurosearch A/S | Imidazole compounds and their use |
KR960702445A (ko) * | 1993-05-20 | 1996-04-27 | 간자와 무츠오 | 1-(2-벤조이미다졸일)-1, 5- 디아자시클로옥탄 유도체(1-(2-benzimidazo-lyl)-1,5-diazacyclooctane compounds) |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
BR9907951A (pt) * | 1998-03-06 | 2001-01-30 | Janssen Pharmaceutica Nv | Inibidores de transporte de glicina |
CA2376785A1 (en) * | 1999-06-28 | 2001-01-04 | Janssen Pharmaceutica N.V. | Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
SK18942001A3 (sk) | 1999-06-28 | 2002-10-08 | Janssen Pharmaceutica N. V. | Inhibítory replikácie respiračného syncytiálneho vírusu |
UA74787C2 (en) | 1999-06-28 | 2006-02-15 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
US7129358B2 (en) | 2001-02-02 | 2006-10-31 | Teva Pharmaceutical Industries Ltd. | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles |
KR20100008799A (ko) | 2001-12-28 | 2010-01-26 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
AU2003247615B2 (en) | 2002-06-24 | 2007-08-09 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
CA2512639C (en) | 2003-01-16 | 2012-10-30 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
DK1723136T3 (da) | 2003-12-18 | 2011-06-27 | Tibotec Pharm Ltd | Piperidinamino-benzimidazol-derivat som inhibitorer af replikation af respiratorisk syncytial virus |
RU2369606C2 (ru) | 2003-12-18 | 2009-10-10 | Тиботек Фармасьютикалз Лтд. | Производные 5- или 6-замещенных бензимидазолов в качестве ингибиторов репликации респираторного синцитиального вируса |
BRPI0417811A (pt) | 2003-12-18 | 2007-03-27 | Tibotec Pharm Ltd | aminobenzimidazóis e benzimidazóis como inibidores da replicação do vìrus sincicial respiratório |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
EP2289879B1 (en) | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2008116024A2 (en) | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
PL3325444T3 (pl) | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2857391A (en) * | 1955-04-15 | 1958-10-21 | Merck & Co Inc | Aminomethylbenzimidazoles |
US2971005A (en) * | 1958-10-17 | 1961-02-07 | Merck & Co Inc | Nu-substituted derivatives of 2-benzylaminobenzimidazoles |
BE788065A (fr) * | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
-
1979
- 1979-03-19 CA CA000323763A patent/CA1140119A/en not_active Expired
- 1979-03-21 AU AU45296/79A patent/AU523352B2/en not_active Expired
- 1979-03-23 NZ NZ189978A patent/NZ189978A/en unknown
- 1979-03-29 DK DK129879A patent/DK169325B1/da not_active IP Right Cessation
- 1979-03-29 GR GR58721A patent/GR64907B/el unknown
- 1979-03-30 CY CY1250A patent/CY1250A/xx unknown
- 1979-03-30 RO RO7997082A patent/RO79320A/ro unknown
- 1979-03-30 EP EP79300525A patent/EP0005318B1/en not_active Expired
- 1979-03-30 DE DE7979300525T patent/DE2961740D1/de not_active Expired
- 1979-04-01 EG EG200/79A patent/EG13913A/xx active
- 1979-04-02 ZA ZA791557A patent/ZA791557B/xx unknown
- 1979-04-02 ES ES479206A patent/ES479206A1/es not_active Expired
- 1979-04-02 IL IL56992A patent/IL56992A/xx unknown
- 1979-04-02 AT AT0242579A patent/AT373887B/de not_active IP Right Cessation
- 1979-04-02 NO NO791097A patent/NO154058C/no unknown
- 1979-04-02 JP JP3844779A patent/JPS54151982A/ja active Granted
- 1979-04-02 FI FI791084A patent/FI64801C/fi not_active IP Right Cessation
- 1979-04-02 CS CS792227A patent/CS256358B2/cs unknown
- 1979-04-03 SU SU792747000A patent/SU1056902A3/ru active
- 1979-04-03 YU YU784/79A patent/YU42484B/xx unknown
- 1979-04-03 PL PL1979214648A patent/PL123380B1/pl unknown
- 1979-04-03 PH PH22344A patent/PH15877A/en unknown
- 1979-04-03 PT PT69429A patent/PT69429A/pt unknown
- 1979-04-03 BG BG7943114A patent/BG38164A3/xx unknown
- 1979-04-03 HU HU79JA841A patent/HU182965B/hu unknown
- 1979-08-08 IE IE676/79A patent/IE47818B1/en not_active IP Right Cessation
-
1983
- 1983-03-02 YU YU502/83A patent/YU43158B/xx unknown
- 1983-05-26 SG SG298/83A patent/SG29883G/en unknown
-
1984
- 1984-01-12 HK HK31/84A patent/HK3184A/xx not_active IP Right Cessation
- 1984-06-25 NO NO842563A patent/NO154090C/no unknown
-
1985
- 1985-12-30 MY MY46/85A patent/MY8500046A/xx unknown
-
1988
- 1988-06-14 JP JP63144898A patent/JPH01117880A/ja active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO154090B (no) | Nye n-heterocyklyl-4-piperidinaminer som er mellomprodukter ved fremstilling av analoge forbindelser. | |
CA2482655C (en) | Substituted indoles | |
ES2377556T3 (es) | Compuestos que contienen nitrógeno, que tienen actividad inhibitoria quinasa, y composiciones farmacéuticas que los comprenden | |
KR870001509B1 (ko) | 5원 헤테로사이클 고리를 갖는 n-(비사이클 헤테로사이클릴)-4-피페리딘아민의 제조 방법 | |
US4695575A (en) | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines | |
NO160076B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzoksazol- og benzotianolaminderivater. | |
US20040029874A1 (en) | Aromatic amides | |
NO176101B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive N-(3-hydroksy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran eller dihydrobenzodioksin)karboksamidderivater | |
RU2056420C1 (ru) | Производные 1,4-бензодиоксана или их соли и способ их получения | |
SK282406B6 (sk) | N-(4-Piperidinyl) (dihydrobenzofurán alebo dihydro-2H-benzopyrán) karboxamidové deriváty, spôsob a medziprodukty na ich výrobu a farmaceutické prípravky na ich báze | |
CS256366B2 (en) | Method of new 3-(1-piperidinylalkyl)-4h-pyridol(1,2-pyrimidine-4-on derivatives production | |
JP2011506462A (ja) | メラニン凝集ホルモン受容体1アンタゴニストとしてのビス−ピリジルピリドン | |
US5455246A (en) | Piperidine derivatives | |
HU196393B (en) | Process for producing 4-piperidinyl-alkyl-substituted bicyclic condensed oxazol- and thiazol-amine derivatives and pharmaceutical compositions containing them | |
EP1181287A1 (en) | Sulfonamide compounds with pharmaceutical activity | |
CH666033A5 (de) | 1,4-dihydropyridinderivate und deren salze und hydrate, verfahren zur herstellung dieser verbindungen und solche verbindungen enthaltende pharmazeutische praeparate. | |
CA1257597A (en) | Pharmacologically active 3-substituted indole derivatives | |
WO2007114902A2 (en) | Alkylthiobenzylpiperidine compounds | |
NO172118B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktivt n-(omega-substituert -alkyl)-n'-((imidazol-4-yl)alkyl)-guanidin | |
KR20150068960A (ko) | 치환된 카바메이트 화합물 및 일시적 수용체 전위(trp) 채널 길항제로서의 이의 용도 | |
DK169761B1 (da) | N-(4-piperidinyl)substituerede bicyclisk kondenserede 2-imidazolaminderivater, fremgangsmåde til fremstilling deraf og præparater indeholdende disse derivater | |
US4689330A (en) | Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines | |
KR102582197B1 (ko) | 2-([1,2,3]트리아졸-2-일)-벤조산 유도체의 제조 | |
US5130315A (en) | 1-piperazinyl-2-butenes and -2-butynes | |
PL165731B1 (pl) | Sposób wytwarzania nowych 3-(1-tiazolidynylobutylo-4-piperazynylo) -1H-indazoli PL PL PL PL |